IL-32 exists as seven mRNA transcripts that can translate into distinct individual IL-32 variants with specific protein domains. These translated protein domains of IL-32 variants code for specific functions that allow for interaction with different molecules intracellularly or extracellularly. The longest variant is IL-32γ possessing 234 amino acid residues with all 11 protein domains, while the shortest variant is IL-32α possessing 131 amino acid residues with three of the protein domains. The first domain exists in 6 variants except IL-32δ variant, which has a distinct translation initiation codon due to mRNA splicing. The last eleventh domain is common domain for all seven IL-32 variants. Numerous studies in different fields, such as inflammation, autoimmunity, pathogen infection, and cancer biology, have claimed the specific biological activity of individual IL-32 variant despite the absence of sufficient data. There are 4 additional IL-32 variants without proper transcripts. In this review, the structural characteristics of seven IL-32 transcripts are described based on the specific protein domains.
SEVEN IL-32 VARIANTS WITH ELEVEN PROTEIN DOMAINS
Seven IL-32 variant proteins are described in this review and each IL-32 variant is translated from its distinct messenger RNA (mRNA) transcript. An individual protein domain is numbered by the order of N-terminal initiation and early termination in conjunction with the gradated protein map on the top of Fig. 1 . The seven IL-32 variant proteins are composed of any of 11 protein domains, which may be associated with a particular activity of individual IL-32 variant. The amino acid sequence of domain 3 and 11 exists in all seven IL-32 variants. Seven IL-32 variants were exhibited by the length of amino acid sequence and the number of amino acid residues is indicated on the right (Fig. 1) . IL-32γ is the longest variant that consists of 234 amino acid residues while IL-32α is the shortest variant that consists of 131 amino acid residues. IL-32γ contains all of eleven protein domains and possesses the strongest biological activity in inducing inflammatory cytokines, whereas the shortest IL-32α variant contains three protein domains, domain 1, 6, and 11 (1) . The biological activity of shortest IL-32α variant was originally examined because the yield of recombinant IL-32α protein was higher than other recombinant IL-32 variants protein (unpublished data). However, its activity in inducing inflammatory cytokines is weaker than IL-32γ variant (1-3).
The original report characterized IL-32 as an inflammatory cytokine with four IL-32 variants such as IL-32α, IL-32β, IL-32γ, and IL-32δ (4). IL-32ε is the second shortest variant composed of 148 amino acid sequence containing protein domain 2, 7, and 10. The first domain of IL-32ε has four additional amino acid residues "VMSS" compared to the protein domain 1 of other variants. The protein domain 7 of IL-32ε is the shortest domain that consists of 4 amino acid residues "LAEL" (Fig. 2) . IL-32δ has a distinct translation initiation codon due to mRNA splicing while it has domain 8 like IL-32β. Therefore, the biological activity of IL-32δ could be similar to IL-32β variant. It is necessary to investigate whether IL-32δ has a distinct transcriptional regulation since it uses a different translational initiation codon.
The third shortest variant is IL-32θ that is constituted by 168 amino acid residues. IL-32θ consists of protein domain 1, 5, and 10. The domain 10 exists in IL-32ε therefore IL-32θ probably has similar biological activity to IL-32ε. The phylogenetic tree of IL-32 variants in Fig. 3 suggested that IL-32θ is the closest variant to IL-32ε. These two variants are close to IL-32β. Interestingly, the result of phylogenetic tree showed that IL-32γ variant is the most close to IL-32α that is the shortest variant (Fig. 3) . IL-32ζ consists of domain 1, 4, and 9 with 179 amino acid residues that is a single amino acid residue longer than IL-32δ though the first protein domain is different. IL-32ζ has unique domain 4 and 9, which are spliced from the domain 8 ( Figs. 1 and 2 ).
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https://doi.org/10.4110/in.2019. 19 .e8 The second longest variant is IL-32β that consists of 188 amino acid residues. IL-32β variant has the common domain 1 that exists in four IL-32 variants such as IL-32α, IL-32β, IL-32θ, and IL-32ζ variant. IL-32β variant is constituted by two protein domain 1 and 8, which are spliced from IL-32γ variant since IL-32β transcript has been found in human IL-32γ variant overexpressed transgenic mouse (unpublished data). This data suggested that the splicing of full length IL-32γ transcript could generates IL-32β variant, which possesses 46 amino acid residues less than IL-32γ variant (Fig. 2) . The biological activity of IL-32β is between IL-32α and IL-32γ (1). Multiple alignments of seven IL-32 variants using amino acid sequence. The amino acid sequences of seven IL-32 variants were aligned using program CLUSTALW at website (https://expasy.org/tools). The amino acid residues exist all of seven variants marked by symbol at the bottom. The mRNA transcript of seven IL-32 variants was pictured with essential information such as transcript and protein size in Fig. 4 . The top row identified variant name, transcript identity (ID), mRNA transcript size by base pair (bp), protein length by the number of amino acid residue, accession number in UniPort, and accession number in database. IL-32β variant is the most abundant IL-32 transcript among seven IL-32 variant highlighted by yellow color that has four reference sequences in database. IL-32θ variant highlighted by green color has 2 reference transcripts with amino acid sequences in database. IL-32α, IL-32γ, and IL-32ζ variant have a single transcript with reference sequence, while IL-32δ and IL-32ε variant do not have the reference sequence of transcript in database (Fig. 4, highlighted by gray color) .
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IL-32 VARIANTS IN DIFFERENT DISEASES
IL-32 is generally considered to be an inflammatory cytokine since early IL-32 research suggested that it is an inducer of TNFα. Therefore many investigators approached the effect of IL-32 in Th1 autoimmune-associated diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis (5-8). The majority of clinical studies depend on the measurement of circulating IL-32 levels in the plasma or serum of patients comparing to normal individuals. The limitation of this type of study cannot distinguish IL-32 variants, which may possess a distinct potency in inflammatory activity as well as different functions in diseases.
Relatively small numbers of IL-32-associated Th2 autoimmune diseases have been reported (9) (10) (11) . These studies were initiated later comparing to Th1 autoimmune diseases related with IL-32. Unlike IL-32-mediated Th1 autoimmune diseases, the mechanism of IL-32-associated Th2 autoimmune diseases is unclear and not well understood. 
ENST .
ENST . activity in Th2 autoimmune disease may be an outcome of Th2 inflammation rather than a cause of the disease. Further investigation with specific IL-32 variants may clarify the role of IL-32 in Th2 autoimmune diseases, such as asthma and atopic dermatitis. Few reports with other autoimmune diseases have been studied with limited information (12) .
Various reports with IL-32 in cancer have been investigated with the mouse model of human IL-32α, IL-32β, and IL-32γ variant overexpressed transgenic mice (5, 13, 14) . These studies explained the importance of IL-32 role in cell growth by different mechanisms including cell apoptosis. IL-32 genes have been found in most mammals except rodent (15 (8, 24) . This data support that IL-32 exhibits biological activity with only myeloid cells in inducing inflammatory cytokines.
CONCLUSION
Over three hundred publications have been reported with IL-32 since the first publication in 2005. The most studied variant is IL-32γ followed by IL-32α and IL-32β variant. IL-32β variant is the most abundant variant in Fig. 4 , though less numbers of studies. There is some limitation to identify IL-32 variant at protein level because the lack of specific antibody to detect IL-32 variant. IL-32 variant expression pattern and its regulation could be identified with variant specific primers rather than protein level. There are four additional IL-32 variants in the absence of report (data not shown). Further investigation of IL-32 variant expression pattern and characterization of IL-32 variant domain specific activity in human diseases will help understand to clarify IL-32 variant-associated autoimmune and infectious diseases.
